BBAL (BBAL) Stock Price & Analysis
BBAL (BBAL) rose 0.00% to USD 0 as of June 10, 2026 at 00:55 UTC, according to Nexqual real-time market data.
BBAL last closed at USD 0; the session ranged USD 0–0 on volume of 350 shares. Market capitalization is $335,327, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 00:55 UTC.
Key Statistics (as of June 10, 2026 at 00:55 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 350 shares |
| Market Cap | $335,327 |
| Exchange | PNK |
Technical Analysis (BBAL)
Nexqual's technical model rates BBAL "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:55 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (BBAL)
Wall Street analysts rate BBAL "None", per Nexqual as of June 10, 2026 at 00:55 UTC.
| Consensus Rating | None |
|---|
Earnings (BBAL)
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Financials & Fundamentals (BBAL)
| Total Revenue | $45.78M |
|---|---|
| Revenue Growth (YoY) | -1.70% |
| Gross Margin | +16.05% |
| Operating Margin | -2.08% |
| Profit Margin | +0.48% |
| Current Ratio | 0.77 |
| Total Cash | $5.37M |
| Total Debt | $0 |
| Free Cash Flow | $3.76M |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Financial Health Score (BBAL)
Nexqual rates BBAL's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:55 UTC.
| Growth | Weak — Revenue -2% YoY (latest Q), declining |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $5M cash, no debt |
| Cash Flow | Solid — FCF $4M, 8% margin |
| Efficiency | Mixed — No data |
Ownership (BBAL)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 0 |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Leadership (BBAL)
BBAL is led by Murray Englard (age 65), Chief Executive Officer and Director, per Nexqual as of June 10, 2026 at 00:55 UTC.
| Chief Executive Officer and Director | Murray Englard (age 65) |
|---|
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NTII | NEUROBIOLOGICAL TECHNOLOGIES IN | USD 0 | ▲ 0% |
| HMGN | HEMAGEN DIAGNOSTICS INC | USD 0 | ▲ 0% |
| AOLS | AEOLUS PHARMACEUTICALS INC | USD 0 | ▲ 0% |
| AVTI | AVITAR INC | USD 0 | ▲ 0% |
| ACUS | ACUSPHERE INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:55 UTC. This page is informational and not investment advice.